# To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma

> **NCT01568762** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** VAK694
- **DRUG:** VAK694 placebo
- **DRUG:** QAX576
- **DRUG:** QAX576 placebo

## Key facts

- **NCT ID:** NCT01568762
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2011-07
- **Final completion:** —
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01568762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01568762, "To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01568762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*